文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Fremanezumab 预防发作性偏头痛的随机临床试验

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

该研究在9国123个中心开展随机双盲安慰剂对照试验,纳入875例18至70岁发作性偏头痛患者,比较皮下注射 Fremanezumab 月度方案、单次高剂量方案与安慰剂的疗效。12周内月偏头痛天数较基线下降在三组分别为8.9至4.9天、9.2至5.3天、9.1至6.5天,两种方案相对安慰剂均显著减少月偏头痛天数。

要点

  • 月度方案较安慰剂月偏头痛天数减少1.5天(95%CI -2.01至-0.93,P<.001)
  • 单次高剂量方案较安慰剂减少1.3天(95%CI -1.79至-0.72,P<.001)
  • 此前两类预防药物失败者被排除,结论外推需谨慎

核心结论

  • 在未经历多类预防药物失败的发作性偏头痛患者中,皮下 Fremanezumab 较安慰剂在12周内显著减少月偏头痛天数1.3至1.5天。
  • 作者指出尚需与其他预防药物比较,并在多类预防药物失败者中及长期安全性有效性方面进一步研究。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行分组试验,在9个国家123个中心开展。
  • 筛查访视、28天 pretreatment 期、12周治疗期,第12周终末评估;首例患者随机于2016年3月23日,至2017年4月10日。
  • 共随机875例18至70岁发作性偏头痛患者(28天内6至14个头痛日且至少4个偏头痛日);此前两类偏头痛预防药物失败者被排除。
  • 按1:1:1随机:月度组 n=290(基线、第4、8周各225 mg);单次高剂量组 n=291(基线675 mg,第4、8周安慰剂);安慰剂组 n=294。
  • 791例(90.4%)完成试验;平均年龄41.8岁(SD 12.1),女性742例(85%)。

主要发现

  • 主要终点为首次给药后12周内月偏头痛天数均值的变化。
  • 月度组月偏头痛天数由基线8.9天降至4.9天,单次高剂量组由9.2天降至5.3天,安慰剂组由9.1天降至6.5天。
  • 月度方案相对安慰剂的差值为-1.5天(95%CI -2.01至-0.93天;P<.001)。
  • 单次高剂量方案相对安慰剂的差值为-1.3天(95%CI -1.79至-0.72天;P<.001)。
  • 导致停药的最常见不良事件为注射部位红斑(n=3)、注射部位硬结(n=2)、腹泻(n=2)、焦虑(n=2)、抑郁(n=2)。

临床怎么用

  • 对未经历多类预防药物失败的发作性偏头痛患者,皮下 Fremanezumab 月度或单次高剂量方案可考虑用于预防治疗。
  • 用药决策需结合注射部位反应及腹泻、焦虑、抑郁等不良事件风险进行个体化评估。

局限性

  • 此前两类偏头痛预防药物失败的患者被排除,结论不适用于该类人群。
  • 作者指出仍需与其他预防药物比较,并需明确长期安全性与有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine. OBJECTIVE: To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose. DESIGN AND SETTING: Randomized, double-blind, placebo-controlled, parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient randomized), to April 10, 2017, consisting of a screening visit, 28-day pretreatment period, 12-week treatment period, and final evaluation at week 12. PARTICIPANTS: Study participants were aged 18 to 70 years with episodic migraine (6-14 headache days, with at least 4 migraine days, during 28-day pretreatment period). Patients who had previous treatment failure with 2 classes of migraine-preventive medication were excluded. INTERVENTIONS: Patients were randomized 1:1:1 to receive subcutaneous monthly dosing of fremanezumab (n = 290; 225 mg at baseline, week 4, and week 8); a single higher dose of fremanezumab, as intended to support a quarterly dose regimen (n = 291; 675 mg of fremanezumab at baseline; placebo at weeks 4 and 8); or placebo (n = 294; at baseline, week 4, and week 8). MAIN OUTCOMES AND MEASURES: The primary end point was mean change in mean number of monthly migraine days during the 12-week period after the first dose. RESULTS: Among 875 patients who were randomized (mean age, 41.8 [SD, 12.1] years; 742 women [85%]), 791 (90.4%) completed the trial. From baseline to 12 weeks, mean migraine days per month decreased from 8.9 days to 4.9 days in the fremanezumab monthly dosing group, from 9.2 days to 5.3 days in the fremanezumab single-higher-dose group, and from 9.1 days to 6.5 days in the placebo group. This resulted in a difference with monthly dosing vs placebo of -1.5 days (95% CI, -2.01 to -0.93 days; P < .001) and with single higher dosing vs placebo of -1.3 days (95% CI, -1.79 to -0.72 days; P < .001). The most common adverse events that led to discontinuation were injection site erythema (n = 3), injection site induration (n = 2), diarrhea (n = 2), anxiety (n = 2), and depression (n = 2). CONCLUSIONS AND RELEVANCE: Among patients with episodic migraine in whom multiple medication classes had not previously failed, subcutaneous fremanezumab, compared with placebo, resulted in a statistically significant 1.3- to 1.5-day reduction in the mean number of monthly migraine days over a 12-week period. Further research is needed to assess effectiveness against other preventive medications and in patients in whom multiple preventive drug classes have failed and to determine long-term safety and efficacy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02629861.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018. PMID: 29800211. doi:10.1001/jama.2018.4853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。